Table 3.

Summary of effect size and standardised response mean

	Effect size		Standardised response mean
	Week 24* (N=451)	Week 52† (N=193)	Week 24* (N=451)	Week 52† (N=193)
PASDAS	2.37	3.09	1.63	2.36
DAPSA	1.24	1.64	1.36	1.75
mCPDAI	1.31	1.95	1.09	1.58
GRACE	2.40	3.05	1.61	2.30

Observed data are reported.

Scores ≥0.8 were considered large treatment effects.

*Patients initially randomised to adalimumab or ixekizumab.

†Patients initially randomised to ixekizumab.

DAPSA, Disease Activity index for Psoriatic Arthritis; GRACE, GRAppa Composite scorE; mCPDAI, modified Composite Psoriatic Disease Activity Index; N, number of patients in the analysis population; PASDAS, Psoriatic Arthritis Disease Activity Score.